Lupine’s logo, as is seen on the facade of its pharmaceutical plant in Verna in Goa, India. Image for the purpose of representation. Photo Credit: Reuters
Generic drug manufacturer Lupine has launched Revroxban for oral suspension, 1 mg/mL in the US
This product is bio -form for Xarelto for oral suspension, 1 mg/ml of jansen pharmaceuticals, Inc. The oral suspension for Rivaroxaban, 1 mg/ml (reference -drug Xarelto) had estimated an annual sale of $ 11 million in the US, Lupin said, “Ecuia Matt Stired the number of July 2025.”
Rivroxban for oral suspension is indicated for the treatment of venous thrombombolism (VTE) and the risk reduction of recurrent VTE in pediatrics from birth to pediatric patients is less than 18 years after the initial parenteral anticoagulant treatment of at least 5 days; And the treatment of thromboproflaxis in 2 years and more than the congenital heart disease after the fannon process, it said.
Published – October 01, 2025 08:28 pm IST
